Wednesday, July 8, 2026

biotech · Huntington Disease · Alzheimer Disease · VYGR

Voyager Therapeutics

Voyager Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
Status
Public
HQ
Lexington, USA
Founded
2014
Employees
168
Programs
4
Drugs
4
Patents
31
Intelligence · Clinical Programs

Voyager Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Voyager Therapeutics.

Voyager Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. VP4896

    Voyager Therapeutics

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial
  2. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials
  3. VY7523

    Voyager Therapeutics

    Alzheimer's Disease (AD)

    phase 2 small molecule active

    1 trial
  4. Intraparenchymal rAAV1 - (mi)RNA HTT

    Voyager Therapeutics

    Huntington Disease

    phase 1 gene therapy terminated

    1 trial

Frequently asked questions

How many clinical projects does Voyager Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.